Celltrion’s Remsima challenges to Truxima’s KRW 8 trillion market

On the 19^th(local time), Celltrion announced it received ‘recommendation of approval’ for every indication of the world’s first hematological malignancy anticancer biosimilar Truxima(generic name: rituximab, project name: CT-P10) from Committee for Medicinal Products for Human Use(CHMP), an affiliate of the European Medicines Agency(EMA), on the 16^th.

The company explained the CHMP’s recommend...